title: The hypereosinophilic syndrome: idiopathic or not, that is the question.
authors.forename: Jan
authors.initials: J
authors.lastname: Cools
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D002872:Chromosome Deletion; D002894:Chromosomes, Human, Pair 4 / Q000648:ultrastructure; D002908:Chronic Disease; D002999:Clone Cells / Q000473:pathology; D003937:Diagnosis, Differential; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D008232:Lymphoproliferative Disorders / Q000145:classification; D009196:Myeloproliferative Disorders / Q000145:classification; D015514:Oncogene Proteins, Fusion / Q000096:biosynthesis / Q000235:genetics; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D017434:Protein Structure, Tertiary / Q000235:genetics; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000096:biosynthesis / Q000235:genetics; D019311:Staurosporine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000473:pathology; D039221:mRNA Cleavage and Polyadenylation Factors / Q000096:biosynthesis / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha; D019311:Staurosporine; C059539:midostaurin